| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 249.77B | 250.60B | 242.43B | 239.29B | 223.28B | 202.44B |
| Gross Profit | 97.23B | 92.23B | 92.89B | 91.77B | 87.05B | 78.82B |
| EBITDA | 5.62B | 9.11B | 9.72B | 12.97B | 9.25B | 7.68B |
| Net Income | -1.53B | 971.00M | 2.59B | 5.40B | 3.84B | 412.00M |
Balance Sheet | ||||||
| Total Assets | 212.61B | 205.57B | 210.40B | 211.78B | 208.87B | 207.99B |
| Cash, Cash Equivalents and Short-Term Investments | 22.07B | 19.86B | 24.94B | 32.89B | 39.89B | 44.32B |
| Total Debt | 7.26B | 8.40B | 10.96B | 13.05B | 15.59B | 16.04B |
| Total Liabilities | 91.22B | 83.44B | 85.58B | 89.21B | 90.16B | 91.63B |
| Stockholders Equity | 121.00B | 121.72B | 124.45B | 122.36B | 118.67B | 116.32B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 5.31B | -2.86B | 1.38B | -2.78B | 20.13B |
| Operating Cash Flow | 0.00 | 12.06B | 4.27B | 7.02B | 2.23B | 25.37B |
| Investing Cash Flow | 0.00 | -9.60B | -8.04B | -5.48B | -5.16B | -2.02B |
| Financing Cash Flow | 0.00 | -7.53B | -4.14B | -7.91B | -2.12B | 8.51B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ¥260.93B | 11.87 | 10.61% | 1.81% | 5.29% | 16.34% | |
71 Outperform | ¥86.82B | 5.42 | 6.96% | 2.98% | 1.15% | 86.72% | |
65 Neutral | ¥40.35B | 9.40 | ― | 2.19% | 17.90% | 14.14% | |
63 Neutral | ¥76.68B | 10.29 | ― | 2.11% | 6.04% | 93.19% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
60 Neutral | ¥44.92B | 15.79 | ― | 3.31% | 0.88% | -138.66% | |
43 Neutral | ¥10.31B | -8.39 | ― | 3.08% | 3.31% | -94.69% |
XEBIO Holdings reported net sales of ¥188.8 billion for the nine months to December 31, 2025, essentially flat year on year, but operating profit dropped nearly 59% and profit attributable to owners of parent plunged about 78%, leading to a sharp fall in earnings per share. Despite weaker profitability and a decline in the equity ratio as total assets increased, the company kept its dividend plan intact and maintained full‑year forecasts that assume modest sales growth but significantly lower profits, signaling ongoing margin pressures for shareholders and raising questions about its earnings resilience.
For the full year ending March 31, 2026, XEBIO projects net sales of ¥253.5 billion, up 1.2%, but expects operating profit and ordinary profit to fall by roughly 43% and 33% respectively, with net profit down more than 75%, underscoring a challenging operating environment. While no major changes in consolidation or accounting policies were reported, the combination of rising assets, lower net assets and subdued profit outlook suggests the retailer faces structural headwinds that could weigh on returns and limit financial flexibility in the near term.
The most recent analyst rating on (JP:8281) stock is a Hold with a Yen1171.00 price target. To see the full list of analyst forecasts on XEBIO Holdings CO., LTD. stock, see the JP:8281 Stock Forecast page.